APA (7th ed.) Citation

HA, M., E, W., AR, K., A, L., C, K., A, V., . . . D, F. (2026). Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. Open forum infectious diseases, 13(5), ofag266. https://doi.org/10.1093/ofid/ofag266

Chicago Style (17th ed.) Citation

HA, Mujuru, et al. "Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial." Open Forum Infectious Diseases 13, no. 5 (2026): ofag266. https://doi.org/10.1093/ofid/ofag266.

MLA (9th ed.) Citation

HA, Mujuru, et al. "Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial." Open Forum Infectious Diseases, vol. 13, no. 5, 2026, p. ofag266, https://doi.org/10.1093/ofid/ofag266.